Want to see FSNUY full AI Analyst Report?
FSNUY Stock Chart & Stats
$14.04
$0.06(0.63%)
At close: 4:00 PM EST
$14.04
$0.06(0.63%)
Day’s Range― - ―
52-Week Range$10.30 - $15.39
Previous CloseN/A
Volume6.04K
Average Volume (3M)1.96K
Market Cap
$26.62B
Enterprise Value$40.89K
Total Cash (Recent Filing)$2.06B
Total Debt (Recent Filing)$11.92B
Price to Earnings (P/E)15.7
Beta0.37
Next Earnings
Aug 05, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend Yield1.97%
Share Statistics
EPS (TTM)0.16
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume1,958
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)5.76
Price to Sales (P/S)5.00
P/FCF Ratio95.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.01
Revenue Forecast (FY)$27.35B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare ModelFresenius operates across dialysis care, pharma/biologics manufacturing, and hospital services, creating multiple regulated revenue streams. This structural diversification smooths cycle exposure, supports cross-selling and internal procurement, and sustains cash generation across payor systems.
Improving Profitability And LeverageRecent margin and leverage improvement (EBIT & net margins rising; D/E down toward 0.60) increases financial resilience. Stronger margins and lower leverage enhance ability to invest, fund operations and reward shareholders while reducing bankruptcy and refinancing risk over the medium term.
Recovering Free Cash Flow GenerationA meaningful TTM rebound in free cash flow and ~50% conversion of net income to FCF supports capital spending, debt reduction and dividends. Sustained positive FCF provides self-funding capacity and flexibility to absorb reimbursement pressure or invest in growth initiatives.
Bears Say
Earnings And Cash VolatilityPast swings—including a loss in 2023 and uneven annual cash flows—reduce earnings visibility and complicate long-range planning. Structural volatility can hinder capex timing, elevate precautionary liquidity needs and raise borrowing costs during adverse cycles.
Modest Returns On CapitalMid-single-digit ROE and mid-range margins limit the company's internal capacity to fund high-return expansion. Modest returns can pressure management to pursue external financing or acquisitions to meet growth targets, risking dilution or added leverage.
Operating Cash Flow Intensity Is ModestA relatively low operating cash flow margin and variability in FCF mean the business is somewhat cash intensive. This constrains free cash available for strategic initiatives and increases sensitivity to reimbursement changes or volume declines, stressing flexibility in downturns.
Fresenius SE & Co News
FSNUY FAQ
What was Fresenius SE & Co’s price range in the past 12 months?
Fresenius SE & Co lowest stock price was $10.30 and its highest was $15.39 in the past 12 months.
What is Fresenius SE & Co’s market cap?
Fresenius SE & Co’s market cap is $26.62B.
When is Fresenius SE & Co’s upcoming earnings report date?
Fresenius SE & Co’s upcoming earnings report date is Aug 05, 2026 which is in 17 days.
How were Fresenius SE & Co’s earnings last quarter?
Fresenius SE & Co released its earnings results on May 06, 2026. The company reported $0.241 earnings per share for the quarter, missing the consensus estimate of $0.253 by -$0.012.
Is Fresenius SE & Co overvalued?
According to Wall Street analysts Fresenius SE & Co’s price is currently Overvalued.
Does Fresenius SE & Co pay dividends?
Fresenius SE & Co pays a Annually dividend of $0.305 which represents an annual dividend yield of 1.97%. See more information on Fresenius SE & Co dividends here
What is Fresenius SE & Co’s EPS estimate?
Fresenius SE & Co’s EPS estimate is 0.25.
How many shares outstanding does Fresenius SE & Co have?
Fresenius SE & Co has 2,252,949,200 shares outstanding.
What happened to Fresenius SE & Co’s price movement after its last earnings report?
Fresenius SE & Co reported an EPS of $0.241 in its last earnings report, missing expectations of $0.253. Following the earnings report the stock price went up 1.577%.
Which hedge fund is a major shareholder of Fresenius SE & Co?
Currently, no hedge funds are holding shares in FSNUY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
FSNUY Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.93%
12-Months-Change
Fundamentals
Return on Equity
7.76%
Trailing 12-Months
Asset Growth
4.60%
Trailing 12-Months
Company Description
Fresenius SE & Co
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
Technical Analysis
DaVita
―
Fresenius Medical Care
―
HCA Healthcare
―
Tenet Healthcare
―
Universal Health
―